If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
236
results.
Updated on
14/07/2025 [06:52:00]
Results 125 to 150 of 236
Absstract of: AU2024224059A1
The present invention relates to the use of a composition comprising a neo-synthesized extracellular matrix for the treatment of cancer, in particular for the inhibition of cancer viability, migration and proliferation.
Absstract of: US2025213472A1
An immunomodulatory hydrogel is prepared using methoxy polyethylene glycol amine (mPEG-NH2) as an initiator, the mPEG-NH2 reacts with L-tyrosine-N-carboxyanhydrides (L-Tyr-NCAs) to form a methoxy polyethylene glycol-poly L-tyrosine (PETyr) as a PETyr block copolymer. The PETyr is then reacted with tyrosinase to form an oxidized methoxy polyethylene glycol-poly L-tyrosine copolymer (PETO). By co-dissolving the PETO with octyl itaconate nanomicelles (ITA8) in a disperse medium, an itaconic acid-loaded immunomodulatory hydrogel (PETO-ITA8) is obtained.
Absstract of: TW202438044A
A compound having the following structure of Formula (I): or a stereoisomer, salt, or tautomer thereof, wherein R1, R2, R3, R4, R5, R6, G1, G2, x, y, n, z, and w are as defined herein. Compositions comprising the compounds, and their use in methods of treating diseases, are also described.
Absstract of: WO2024135604A1
The object of the present invention is to provide a method for delivering a therapeutic agent to endothelial cells, mesenchymal cells, or cancer cells which can realize excellent delivery efficiency to organs other than the liver, and a composition containing a therapeutic agent and lipid nanoparticles which can realize excellent delivery efficiency to an organ other than the liver. The present invention provides a method for delivering a therapeutic agent to endothelial cells, mesenchymal cells, or cancer cells, which comprises administering a lipid composition to a subject, wherein the lipid composition comprises the therapeutic agent and lipid nanoparticle, and wherein the lipid nanoparticle comprises an ionizable lipid and a compound represented by formula (1) or a salt thereof. (1) wherein G1 represents -C(O)-, -OC(O)-, -O(CO)O- or -C(O)O-, LY represents a single bond, an alkylene group having 1-14 carbon atoms, a substituted alkylene group having 1-14 carbon atoms, a heteroalkylene group having 1-14 carbon atoms, and a substituted heteroalkylene group having 1-14 carbon atoms. X represents a basic functional group.
Absstract of: US2025214953A1
The disclosure relates to a novel sulfide-containing ionizable lipid. The ionizable lipid of the disclosure interacts electrostatically with an anionic drug when a lipid nanoparticle is produced, thereby ensuring that the drug is encapsulated in the lipid nanoparticle with high efficiency and the drug is stably delivered into the body, facilitating its utility in the related art such as lipid nanoparticle-mediated gene therapy.
Absstract of: US2025214925A1
Disclosed is a cationic lipid having the following general formula (I), wherein A, B, C, and D are each as defined in the description. Also disclosed are a liposome and a lipid nanoparticle containing the cationic lipid, and use of the cationic lipid in the preparation of the liposome and the lipid nanoparticle.
Absstract of: US2025213719A1
Described herein are compositions, systems, and methods for targeted and controlled drug release. In some embodiments, the compositions, systems, and methods may comprise magnetoelectric silica nanoparticles for targeted and controlled release of chemotherapeutic drugs for cancer treatment. In some embodiments, an external magnetic field may be used to release one or more drugs from the magnetoelectric silica nanoparticles. The disclosed compositions, systems, and methods may improve drug targeting and reduce systemic drug toxicity.
Absstract of: US2025213718A1
New lipids are provided that are useful for delivering macromolecules, such as nucleic acids, into eukaryotic cells and tissue. The lipids can be used alone, in combination with other lipids and/or in combination with other transfection enhancing reagents to prepare transfection complexes and complexes for in vivo delivery of bioactive agents.
Absstract of: US2025213717A1
Formulations for improved delivery of therapeutic virus-like particles containing therapeutic peptides are provided. Method for making the formulations and use thereof, are further provided.
Absstract of: US2025213596A1
Provided is a composition comprising at least one carrier comprising a nanoporous material; and at least one cannabinoid and at least one non-cannabinoid, non-terpene impurity, wherein a concentration of carrier is between about 30 wt % and about 90 wt % of the total composition; a concentration of the cannabinoid is between about 10 wt % and about 70 wt % of the total composition; a combined concentration of the cannabinoid and the carrier is at least about 80 wt % of the total composition; at least about 90 wt % of the cannabinoid is adsorbed on the carrier; a ratio between a total weight of the cannabinoid and a total weight of the at least one impurity is at least about 1.5:1; and the carrier comprises discrete particles. Further provided are methods of preparation and methods of use of the composition.
Absstract of: US2025213638A1
Pain relief compositions are described for topical application to penetrate deep into the skin, muscles, and joints. The pain relief compositions are prepared as creams for topical applying to the skin. The pain relief compositions contain active ingredients such as DMSO, capsaicin, menthol, eucalyptus extract, chamomile oil, methyl salicylate, and cayenne oil. One or more of the active ingredients is included in the pain relief composition as nanoparticles. Methods for preparing and for using the pain relief compositions are also described.
Absstract of: US2025213610A1
Compositions and methods are described in which a water-soluble fullerene (preferably a water-soluble buckminsterfullerene or C60) is used in combination with an associated ketone in order to treat central nervous system disease or injury. The associated ketone can be noncovalently coupled to the outer surface of the water-soluble fullerene, covalently coupled to the outer surface of the water-soluble fullerene, and/or encapsulated or otherwise held within the interior volume of the water-soluble fullerene. Such formulations are effective in increasing neuronal activity in damaged portions of the central nervous system, reduce fatigue, and increase endurance.
Absstract of: US2025213671A1
An iRNA and/or iDNA vaccine system and/or platform are described for eliciting an immune response against one or more pathogens. Also described, are methods of making and using the iRNA and/or iDNA vaccine system and/or platform.
Absstract of: US2025213665A1
The invention relates to therapeutic nanobiologic compositions and methods of treating patients who have had an organ transplant, or who suffer from atherosclerosis, arthritis, inflammatory bowel disease including Crohn's, autoimmune diseases including diabetes, and/or autoinflammatory conditions, or after a cardiovascular events, including stroke and myocardial infarction, by inhibiting trained immunity, which is the long-term increased responsiveness, the result of metabolic and epigenetic re-wiring of myeloid cells and their stem cells and progenitors in the bone marrow and spleen and blood induced by a primary insult, and characterized by increased cytokine excretion after re-stimulation with one or multiple secondary stimuli.
Absstract of: US2025213479A1
The present invention is an improvement in Lipid Nanoparticles (LNPs) for re-routing their distribution from the liver and spleen (the non-target organs) to hard-to-deliver targets such as the brain and other tissues for drug delivery. Specifically, the invention derivatizes or otherwise modifies LNPs to provide the surface or constituency thereof with “Ionic Liquid” (IL) so that the IL-LNP incorporates an ionizable lipid such as a cationic ionizable lipid, an optional helper lipid, cholesterol and a (true) ionic liquid component. Among other benefits of the inclusion of “Ionic Liquid” is to decrease the delivery of LNPs to the body's filtering organ—the liver—and thereby re-route delivery to other target organs.
Absstract of: US2025213680A1
The present disclosure relates to a lipid nanoparticle composition including a gallic acid derivative lipid and a use thereof, wherein it is possible to improve delivery efficiency and immune effect by changing some of the compositions of lipid nanoparticles using a bio-friendly gallic acid derivative lipid and, in particular, if a gallic acid derivative replaces a certain ratio of an ionizable lipid in a molar composition ratio, it is possible to mitigate toxicity generated by the ionizable lipid, so as to be utilized for drug delivery more safely in vivo.
Absstract of: US2025213678A1
Proposed is a new vaccine development platform using plant-secreted nano-vesicles for delivery of recombinant proteins and mRNA. It was confirmed that the delivery efficiency of the hepatitis B virus surface antigen (HBsAg) (drug) was higher when loaded onto nano-vesicles isolated from grapefruit or mandarin orange, compared to administering the antigen alone. Thereby, the nano-vesicles can be utilized as a composition for drug delivery.
Absstract of: US2025213473A1
The present invention provides a method of preparing a lipid nanoparticle dispersion using a twin screw extruder. The inventive DNLF fluids are isotropic fluids which include greater than 25% lipophilic content in the form of lipidic nanoparticles dispersed in a continuous aqueous matrix with turbidity less than 375 nephelometric turbidity units (NTU).
Absstract of: US2025213474A1
This disclosure provides compositions and methods for stimulating the innate immune response in a subject with agents capable of stimulating an innate immune response in a subject upon administration to the subject (e.g., damage-associated molecular patterns (DAMPs) and pathogen-associated molecular patterns (PAMPs)). In particular, the present invention is directed to compositions of DAMPs/PAMPs and metals ions, as well as systems and methods utilizing such nanoparticles (e.g., in diagnostic and/or therapeutic settings).
Absstract of: US2025213495A1
Methods of preparing lyophilized lipid nanoparticle-nucleic acid compositions are provided. The methods comprise preparing a suspension of lipid nanoparticles with a monosaccharide and one or more excipients selected from thiosulfate, potassium sorbate, sodium benzoate, and iodixanol. Lyophilized lipid nanoparticle-nucleic acid compositions and methods of reconstituting and administering the same are further provided.
Absstract of: US2025213664A1
The disclosure features lipid nanoparticle (LNP) compositions comprising checkpoint cancer vaccines and uses thereof. The LNP compositions of the present disclosure comprise mRNA therapeutics encoding checkpoint cancer vaccine comprising IDO and PD-L1 antigenic peptides. The LNP compositions of the present disclosure can induce an immune response and stimulate T effector cells in vivo and, accordingly are useful in treating cancer.
Absstract of: US2025213477A1
A cationic lipid compound, a preparation method and a use thereof, and a delivery system for mRNA are provided. The cationic lipid compound has a structure represented by formula (I):In formula (I): X is O or N; n is 2-4; m is 2-4; a is 0 or 1; R1 is a chain structure comprising a tertiary amine; R2 is a linear fatty acyl group or a branched chain fatty acyl group; R3 is a branched chain fatty acyl group. The cationic lipid compound is used for preparing a delivery system for mRNA.
Absstract of: TW202438043A
A compound having the following structure of Formula (I): or a stereoisomer, salt, or tautomer thereof, wherein R1, R2, R3, R4, X, Y1, and Y2 are as defined herein. Compositions comprising the compounds, and their use in methods of treating diseases, are also described.
Absstract of: US2025213478A1
The present invention provides a cationic lipid that can be used as a nucleic acid delivery carrier with good intracellular dynamics, a lipid membrane structure containing the same, a nucleic acid-introducing agent and a pharmaceutical composition containing any of them, a method for introducing nucleic acid into cells or target cells, and a method for producing a cell medicine. A cationic lipid represented by the formula (1) (definitions of symbols in the formula are as described in the specification), a lipid membrane structure using the aforementioned cationic lipid, a nucleic acid-introducing agent and a pharmaceutical composition using the aforementioned cationic lipid or the aforementioned lipid membrane structure, a method for introducing nucleic acid into cells or target cells by using the aforementioned nucleic acid-introducing agent, and a method for producing a cell medicine by using the aforementioned nucleic acid-introducing agent.
Nº publicación: US2025213496A1 03/07/2025
Applicant:
INST OF CHEMISTRY CHINESE ACADEMY OF SCIENCES [CN]
PROXYBIO THERAPEUTICS CO LTD [CN]
INSTITUTE OF CHEMISTRY, CHINESE ACADEMY OF SCIENCES,
PROXYBIO THERAPEUTICS CO., LTD
Absstract of: US2025213496A1
A lipid nanoparticle and a preparation method and use thereof are provided. The lipid nanoparticle (LNP) includes a carrier and an encapsulated nucleic acid, the carrier includes an ionizable lipid, a helper phospholipid, a PEGylated lipid, cholesterol and its derivatives, and a retinoid compound; and the nucleic acid is one or more of mRNA, circRNA, siRNA, microRNA, antisense nucleic acid, and plasmid.
BOPI
Electronic site
